Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

News, features, and commentary about cancer-related issues ...

Longtime friends and allies of Joe Biden say they are worried about the toll an aggressive form of prostate cancer is taking on the former president and his health. But Biden and his aides say he is ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...